• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
House Dust Mite Allergy - Pipeline Review, H2 2012 Product Image

House Dust Mite Allergy - Pipeline Review, H2 2012

  • Published: October 2012
  • 51 pages
  • Global Markets Direct

House Dust Mite Allergy – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'House Dust Mite Allergy - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for House Dust Mite Allergy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for House Dust Mite Allergy. House Dust Mite Allergy - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for House Dust Mite Allergy.
- A review of the House Dust Mite Allergy products under development READ MORE >

2
List of Tables 4
List of Figures 5
Introduction 6
REPORT COVERAGE 6
House Dust Mite Allergy Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for House Dust Mite Allergy 8
House Dust Mite Allergy Therapeutics under Development by Companies 10
Late Stage Products 12
Comparative Analysis 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Discovery and Pre-Clinical Stage Products 14
Comparative Analysis 14
House Dust Mite Allergy Therapeutics – Products under Development by Companies 15
Companies Involved in House Dust Mite Allergy Therapeutics Development 16
Merck & Co., Inc. 16
ALK-Abello A/S 17
Stallergenes S.A. 18
Circassia Holdings Ltd. 19
ImVisioN Therapeutics AG 20
Genetic Immunity, LLC 21
ANERGIS SA 22
Bial - Portela & Ca, S.A. 23
Biomay AG 24
House Dust Mite Allergy – Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
ToleroMune House Dust Mite T Cell Vaccine - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Mitizax - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Actair - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
MK-8237 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
IVN-Mite - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
DermAll-HDM - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
House Dust Mite Peptide Carrier Fusion Vaccine - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
House Dust Mite RNA Vaccine - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
House Dust Mite Hypoallergenic Vaccine - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
AllerDM - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
PL-103 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
BIA-15-2957 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
House Dust Mite Allergy Therapeutics – Drug Profile Updates 45
House Dust Mite Allergy – Product Development Milestones 49
Featured News & Press Releases 49
Oct 15, 2011: Circassia Initiates Key Phase II Clinical Trial Of House Dust Mite Allergy Treatment 49
Appendix 50
Methodology 50
Coverage 50
Secondary Research 50
Primary Research 50
Expert Panel Validation 50
Contact Us 51
Disclaimer 51

List of Tables
Number of Products Under Development for House Dust Mite Allergy, H2 2012 8
Products under Development for House Dust Mite Allergy – Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 11
Comparative Analysis by Late Stage Development, H2 2012 12
Comparative Analysis by Mid Clinical Stage Development, H2 2012 13
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 14
Products under Development by Companies, H2 2012 15
Merck & Co., Inc., H2 2012 16
ALK-Abello A/S, H2 2012 17
Stallergenes S.A., H2 2012 18
Circassia Holdings Ltd., H2 2012 19
ImVisioN Therapeutics AG, H2 2012 20
Genetic Immunity, LLC, H2 2012 21
ANERGIS SA, H2 2012 22
Bial - Portela & Ca, S.A., H2 2012 23
Biomay AG, H2 2012 24
Assessment by Monotherapy Products, H2 2012 25
Assessment by Stage and Route of Administration, H2 2012 27
Assessment by Stage and Molecule Type, H2 2012 29
House Dust Mite Allergy Therapeutics – Drug Profile Updates 45

List of Figures
Number of Products under Development for House Dust Mite Allergy, H2 2012 8
Products under Development for House Dust Mite Allergy – Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10
Late Stage Products, H2 2012 12
Mid Clinical Stage Products, H2 2012 13
Discovery and Pre-Clinical Stage Products, H2 2012 14
Assessment by Monotherapy Products, H2 2012 25
Assessment by Route of Administration, H2 2012 26
Assessment by Stage and Route of Administration, H2 2012 27
Assessment by Molecule Type, H2 2012 28
Assessment by Stage and Molecule Type, H2 2012 29

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos